Skip to main content
. 2002 Sep 3;99(19):12269–12274. doi: 10.1073/pnas.192445899

Fig 3.

Fig 3.

Expression and methylation of the MYO18B gene in cancerous and noncancerous lung cells. (A) Restoration of MYO18B expression after treatment with 5-aza-dC and/or TSA in 14 cell lines with reduced (or without) MYO18B expression. N, no treatment; 1, 5-aza-dC treatment; 2, TSA treatment; 3, 5-aza-dC and TSA treatment. Each result is the average of two independent tests. * indicates expression levels were more than twice as much as basal levels. (B) Bisulfite sequencing of the 5′ CpG-rich region of the MYO18B gene in lung cancer cell lines without (ABC-1 and PC-3) or with (Ms18, H1299, and H82) MYO18B expression and two normal lung tissues (NL-1 and NL-2). Each circle indicates a CpG site in the primary DNA sequence, and each line of circles represents analysis of a single cloned allele. The numbers of the CpG site are indicated at the top and are identical to the numbers in Fig. 5. ○, unmethylated CpG sites; •, methylated CpG sites; arrow, transcription start site. (C) Methylation status at CpG 10/11 in normal lung tissues and lung cancer cells. The ranges of 50% methylation (n = 7, mean ± 3 SD) at CpG 10/11 are shaded. Paired cancerous and noncancerous lung tissues are connected with solid lines. Samples with MYO18B mutation, square; samples with or with reduced (or without) MYO18B expression, filled in red or blue, respectively. Open squares and circles indicate samples in which MYO18B expression was not determined. Groups N, P, and C indicate normal lung tissue (n = 6), primary tumor (n = 40), and cell line (n = 47), respectively.